关于在澳大利亚和新西兰预防细菌性性传播感染的多西环素接触后预防（Doxy-PEP）的临时立场声明-澳大利亚和新西兰艾滋病毒、病毒性肝炎和性健康医学协会（ASHM）。
Interim position statement on doxycycline post-exposure prophylaxis (Doxy-PEP) for the prevention of bacterial sexually transmissible infections in Australia and Aotearoa New Zealand - the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM).
机构信息
The Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine (ASHM), Sydney, NSW, Australia; and The Kirby Institute, University of NSW, Sydney, NSW, Australia; and Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic., Australia; and NSW Health, Sydney, NSW, Australia.
The Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine (ASHM), Sydney, NSW, Australia; and The Kirby Institute, University of NSW, Sydney, NSW, Australia; and Melbourne Sexual Health Centre, Alfred Health, Melbourne, Vic., Australia; and Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.
出版信息
Sex Health. 2023 Apr;20(2):99-104. doi: 10.1071/SH23011.
Recent studies have provided evidence for the effectiveness of using doxycycline (Doxy-PEP) to prevent bacterial sexually transmissible infections (STI), namely chlamydia, gonorrhoea, and syphilis, among gay, bisexual, and other men who have sex with men who have experienced multiple STIs. However, there remain several unanswered questions around potential adverse outcomes from Doxy-PEP, including the possibility of inducing antimicrobial resistance in STIs and other organisms, and the possibility of disrupting the microbiome of people who choose to use Doxy-PEP. This interim position statement from the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine aims to outline the current evidence for Doxy-PEP, and to highlight potential adverse outcomes, to enable clinicians to conduct evidence-based conversations with patients in Australia and Aotearoa New Zealand who intend to use Doxy-PEP.
最近的研究为使用多西环素（Doxy-PEP）预防淋病、梅毒和衣原体等细菌性性传播感染（STI）提供了证据，这些感染在男同性恋、双性恋和其他与男性发生性关系的男性中较为常见，且这些人已经多次感染 STI。然而，关于 Doxy-PEP 可能产生的不良后果，仍有几个未解决的问题，包括它可能导致 STI 和其他生物体产生抗药性，以及它可能破坏选择使用 Doxy-PEP 的人的微生物组。澳大利亚性健康学会、HIV 病毒和性健康医学协会的这份临时立场声明旨在概述 Doxy-PEP 的现有证据，并强调潜在的不良后果，以使澳大利亚和新西兰的临床医生能够与计划使用 Doxy-PEP 的患者进行基于证据的对话。
Zotero 插件